Cell MedX Corp. Share Price Other OTC
Equities
CMXC
US15115X1072
Biotechnology & Medical Research
Sales 2022 | 0.01 0.51 | Sales 2023 | 0 0.23 | Capitalization | 6.29T 5L |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 1,13,51,53,669 x |
Net Debt 2022 | 6L 4.95Cr | Net Debt 2023 | 9L 7.54Cr | EV / Sales 2023 | 32,91,16,944 x |
P/E ratio 2022 |
-9.01
x | P/E ratio 2023 |
-0.01
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20.34% |
Managers | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12/12 |
Yanika Silina
DFI | Director of Finance/CFO | 46 | 24/14/24 |
George Adams
CHM | Chairman | 76 | 23/18/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12/12 |
Dwayne Yaretz
BRD | Director/Board Member | 63 | 27/22/27 |
Joao da Costa
BRD | Director/Board Member | 59 | 08/20/08 |
1st Jan change | Capi. | |
---|---|---|
+25.72% | 5.27TCr | |
+37.49% | 3.9TCr | |
-9.02% | 3.85TCr | |
+28.07% | 3.04TCr | |
-12.26% | 2.64TCr | |
+10.34% | 2.61TCr | |
+44.91% | 1.42TCr | |
+32.49% | 1.26TCr | |
-6.07% | 1.15TCr |